Regenerative & Advanced Therapies

Overview

Peptides are short chains of amino acids that act as signaling molecules in the body. Therapeutic peptides are used to influence specific biological pathways — including growth hormone secretion, tissue repair, immune modulation, and metabolic function. They are widely discussed in health optimization and longevity communities, with a range of evidence levels depending on the specific peptide.

Current Evidence

Evidence varies dramatically by peptide. Some peptides (BPC-157, TB-500) have extensive preclinical data but limited human clinical trials. Growth hormone secretagogues (sermorelin, ipamorelin) have more clinical data. Most peptides used in optimization contexts are not FDA-approved for the indications they are used for, and are obtained through compounding pharmacies or research chemical suppliers.

Potential Benefits

• Targeted signaling — peptides can influence specific pathways with relative precision
• Growth hormone secretagogues may support body composition and recovery
• BPC-157 and TB-500 have shown tissue repair effects in animal models
• Some peptides have anti-inflammatory and neuroprotective properties in preclinical research

Limitations

• Most optimization-use peptides lack robust human clinical trial data
• Regulatory status varies — many are not FDA-approved for the indications they are used for
• Quality control varies significantly between suppliers
• Long-term safety data is limited for most peptides used in optimization contexts

Safety Considerations

• Consult a physician experienced in peptide therapy before use
• Source from reputable compounding pharmacies — not unregulated research chemical suppliers
• Injection technique and sterility are critical — improper injection carries infection risk
• Do not use peptides that stimulate growth hormone if you have active cancer or a history of cancer

Overview

Platelet-rich plasma (PRP) therapy involves drawing a patient's own blood, concentrating the platelet fraction through centrifugation, and injecting the concentrated platelets into a target tissue. Platelets contain growth factors that stimulate tissue repair, angiogenesis, and cellular proliferation. PRP is used in orthopedics, sports medicine, dermatology, and hair restoration.

Current Evidence

PRP has the most clinical evidence in orthopedic applications — particularly for knee osteoarthritis and tendinopathies — where multiple randomized controlled trials have been conducted. Evidence for hair restoration is growing. Evidence for other applications (skin rejuvenation, sexual wellness) is more limited. Results are variable and depend heavily on preparation protocol and injection technique.

Potential Benefits

• Autologous — uses the patient's own blood, minimizing rejection risk
• Strongest evidence in knee osteoarthritis and tendinopathy
• Stimulates local tissue repair through growth factor delivery
• Growing evidence for androgenetic alopecia (hair loss) treatment
• Minimally invasive compared to surgical alternatives

Limitations

• Results are highly variable — preparation protocols and platelet concentrations differ between providers
• Not covered by most insurance plans for optimization applications
• Multiple sessions are typically required
• Evidence quality varies significantly by application

Safety Considerations

• Autologous procedure — infection risk is low but not zero
• Injection site pain and swelling are common temporary side effects
• Avoid NSAIDs before and after treatment — they may reduce platelet activity
• Work with a qualified physician experienced in PRP preparation and injection technique

Overview

Stem cell therapy involves the use of stem cells — undifferentiated cells capable of self-renewal and differentiation into specialized cell types — to repair or replace damaged tissue. Established clinical applications include bone marrow transplantation for hematological conditions. Experimental applications in health optimization and longevity include mesenchymal stem cell (MSC) infusions for anti-aging, joint repair, and immune modulation.

Current Evidence

Bone marrow transplantation is an established, FDA-approved procedure for specific hematological conditions. Experimental MSC therapies for aging and optimization are in early clinical trial phases. Many clinics offering stem cell therapies for anti-aging, joint repair, or general wellness are operating outside of clinical trial frameworks, with limited regulatory oversight. The FDA has taken enforcement action against some unregulated stem cell clinics.

Potential Benefits

• Established applications: bone marrow transplantation for leukemia and other hematological conditions
• Preclinical evidence for tissue repair and anti-inflammatory effects of MSCs
• Potential for addressing root causes of tissue degeneration rather than symptoms
• Active area of research with significant investment in clinical trials

Limitations

• Most optimization applications are experimental — not FDA-approved
• Significant variability in cell preparation, source, and delivery between providers
• Long-term safety data for experimental applications is limited
• Many clinics offering stem cell therapies operate outside of clinical trial frameworks
• Expensive — typically $5,000–$25,000+ per treatment

Safety Considerations

• Only pursue stem cell therapy through FDA-registered clinical trials or established medical centers
• Avoid unregulated clinics offering stem cell treatments without clinical trial oversight
• Risks include infection, immune reactions, and in rare cases tumor formation
• Consult with a physician at an academic medical center before pursuing experimental stem cell therapy

Overview

Exosomes are nanoscale extracellular vesicles secreted by cells that carry proteins, lipids, and RNA between cells — functioning as intercellular communication vehicles. Exosome therapy involves administering concentrated exosomes (typically derived from mesenchymal stem cells) to deliver regenerative signals to target tissues. It is positioned as a potentially more stable and scalable alternative to direct stem cell therapy.

Current Evidence

Exosome research is active and growing, with preclinical evidence for anti-inflammatory, neuroprotective, and tissue repair effects. Human clinical data is very limited — most exosome therapies offered commercially are not FDA-approved and are not supported by robust clinical trial data. The FDA has issued warnings about unapproved exosome products. This is an early-stage field with significant scientific promise but limited clinical validation.

Potential Benefits

• May deliver regenerative signals without the complexity of live cell administration
• Preclinical evidence for anti-inflammatory and tissue repair effects
• Potentially more stable and scalable than direct stem cell therapy
• Active area of research with growing scientific interest

Limitations

• No FDA-approved exosome products for optimization applications
• Clinical evidence in humans is very limited
• Significant variability in product quality and preparation between providers
• FDA has issued warnings about unapproved exosome products

Safety Considerations

• Avoid commercially offered exosome therapies outside of clinical trial settings
• The FDA has taken enforcement action against some exosome product providers
• Consult with a physician at an academic medical center before pursuing exosome therapy
• Long-term safety data does not exist for most commercial exosome products

Overview

Emerging longevity interventions encompass a broad category of experimental approaches targeting the biological hallmarks of aging — including senolytics (drugs that clear senescent cells), NAD+ precursors (NMN, NR), rapamycin (mTOR inhibitor), metformin (AMPK activator), and plasma-based therapies. These interventions are at various stages of clinical investigation and are increasingly discussed in longevity medicine contexts.

Current Evidence

NAD+ precursors (NMN, NR) have human safety data and some evidence for NAD+ level restoration, but clinical outcome data is limited. Rapamycin has the most robust longevity evidence in animal models of any drug, and is being studied in human trials (PEARL trial). Senolytics (dasatinib + quercetin) have early human data showing senescent cell clearance. Metformin is being studied in the TAME trial for aging. Most of these interventions are used off-label by longevity physicians.

Potential Benefits

• NAD+ precursors: evidence for NAD+ level restoration, which declines with age
• Rapamycin: most robust longevity evidence in animal models of any drug; human trials ongoing
• Senolytics: early human evidence for senescent cell clearance — a hallmark of aging
• Metformin: epidemiological evidence for reduced cancer and cardiovascular risk in diabetics; TAME trial ongoing
• These interventions target root causes of aging rather than individual diseases

Limitations

• Most are used off-label — not FDA-approved for longevity applications
• Human clinical trial data is limited for most interventions
• Long-term safety profiles in non-diabetic, non-diseased populations are not established
• Optimal dosing, timing, and cycling protocols are not standardized

Safety Considerations

• These interventions should only be pursued under the supervision of a physician experienced in longevity medicine
• Rapamycin is an immunosuppressant — infection risk and drug interactions must be carefully managed
• Metformin can cause B12 depletion with long-term use — monitor B12 levels
• Do not self-administer experimental longevity interventions without medical supervision